Is Becton, Dickinson & Co. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 2.52, and an EV to EBITDA of 16.57. In comparison, Abbott Laboratories, which is fairly valued, has a P/E ratio of 18.36, while Stryker Corp., also expensive, has a P/E of 33.17.
Becton, Dickinson & Co. has underperformed relative to the S&P 500, with a year-to-date return of -16.65% compared to the index's 13.30%, and a five-year return of -18.16% against the S&P 500's 91.29%. This performance further reinforces the notion that the stock is currently overvalued.